860724-22-7

Basic information

• Product Name: 3,4,5-triethoxybenzaldehyde
• Synonyms: 3,4,5-triethoxybenzaldehyde
• CAS NO: 860724-22-7
• Molecular Weight: 238.284
• Mol File: 860724-22-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3,4,5-triethoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4,5-triethoxybenzaldehyde(860724-22-7)
• EPA Substance Registry System: 3,4,5-triethoxybenzaldehyde(860724-22-7)

Safety Data

• Hazardous Substances Data: 860724-22-7(Hazardous Substances Data)

Upstream product

• 50915-97-4 3,4,5-triethoxybenzoyl chloride 
• 74-96-4 ethyl bromide 
• 62040-18-0 5-hydroxyethylvanillin 
• 6312-82-9 3-ethoxy-4-hydroxy-5-iodobenzaldehyde 
• 121-32-4 4-hydroxy-3-ethoxybenzaldehyde 
• 39727-75-8 3,4,5-triethoxybenzyl alcohol 
• 6970-19-0 3,4,5-triethoxybenzoic acid 
• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 13677-79-7 gallaldehyde 

Downstream Products

• 90109-63-0 3,4,5-triethoxyphenethylamine 
• 85258-99-7 5-(3,4,5-Triethoxy-phenyl)-thiazolidine-2,4-dione 

Relevant articles and documents

Highly Stereoselective Synthesis of trans -Dihydronarciclasine Analogues

Several new trans -dihydronarciclasine analogues were stereo selectively synthesised by applying our feasible and efficient process developed recently. These new phenanthridone alkaloid derivatives were obtained in both racemic and optically active forms. During their enantioselective syntheses, high selectivities (up to 99% ee) were achieved by using (8 S,9 S)-9-amino(9-deoxy)epiquinine as an organocatalyst. The modifications, the introduction of ethoxy or methoxy groups, were made in ring A of the phenanthridone scaffold.

Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis

Hit compounds from in silico screening for inhibitors of the EGFR dimerization process were evaluated for their anti-proliferative (CCD-1106 keratinocytes) and anti-oxidant (TBA assay) activity and their effect on EGFR dimerization (BS3 chemical crosslinking assay). 7-Benzyl-8-{N′- [1-(3-ethoxy-4-hydroxyphenyl)meth-(Z)-ylidene]hydrazino}-1,3-dimethylxanthine 2a (127 μM) leads to 37% inhibition of p-EGFR dimerization in the CCD-1106 cell line and also inhibits phosphorylation of proteins in the MAPK/ERK pathway, ERK 1/2 and p-38. Based on this initial data, 2a was selected for further study and was evaluated for its anti-proliferative activity in a range of keratinocyte (CCD-1106, HaCaT and NHEK) and monocyte (ThP1 and U937) cell lines. Xanthine 2a is pro-apoptotic in HaCaT keratinocytes, as shown by electron microscopy, caspase 3/7, and annexin V-FITC/PI flow cytometric assays. It is significantly less cytotoxic than the established antipsoriatic agent dithranol 14, as determined by MTT and LDH release assays, and thus has potential as a lead compound for the treatment of psoriasis.